Skip to content

Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma

Effect of Portal Vein Embolization on Surgical Outcomes and Long-term Survival in Patients With Perihilar Cholangiocarcinoma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06222619
Enrollment
136
Registered
2024-01-25
Start date
2020-01-30
Completion date
2023-08-30
Last updated
2024-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Tract Cancer, Portal Vein Embolization

Brief summary

Portal vein embolization is often recommended to reduce the risk of postoperative liver failure and mortality. In this retrospective cohort study, researchers investigated the effect of portal vein embolization in patients with resectable perihilar cholangiocarcinoma bismuth type III and IV.

Interventions

PROCEDUREPotal vein embilization

Portal vein of involved bile duct is embolized to increase the volume of remnant liver.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. patients with Bismuth type III or IV stricture on radiological examination, including computed tomography (CT) or magnetic resonance cholangiography 2. patients with perihilar cholangiocarcinoma histologically confirmed by surgical resection or forceps biopsy/brush cytology under endoscopic retrograde cholangiopancreatography or through the percutaneous transhepatic biliary drainage tract.

Exclusion criteria

1. patients with unresectable perihilar cholangiocarcinoma 2. patients who refused treatment 3. patients with other concomitant malignancies.

Design outcomes

Primary

MeasureTime frameDescription
Overall survivalThe time from diagnosis until the date of death or last date of follow-up or end of study up to 24 monthsOverall survival of each group (A-C).

Secondary

MeasureTime frameDescription
Recurrence free survivalThe time from surgical resection until the date of recurrence or death or last date of follow-up or end of study up to 24 monthsRecurrence free survival of patients who underwent surgical resection

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026